Pharmaceutical Technology

APRIL 24, 2023

There, the data shows that patients on this regimen live longer lives along with having a greater period of time before disease progression, than with other treatments. CLL is regarded as the most common type of leukaemia in England where 3,157 patients were diagnosed with the disease in 2017, based on the institute’s announcement.

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Marketing 52

Marketing Physicians Leads Sales 52

pharmaphorum

NOVEMBER 24, 2022

The phase 3 ESCAPE-TRD study in 676 patients revealed that significantly more of those treated with Spravato were able to achieve remission from symptoms of depression without a relapse over 32 weeks of follow-up compared to quetiapine. and 14.1%, respectively.

Sales 52

Sales Patients Competition Marketing 52

Pharmaceutical Technology

MAY 19, 2023

However, in the second year of biosimilar competition, Rituxan sales started to significantly erode. GlobalData forecasts Rituxan sales to plummet to just over $300m by 2029, while biosimilars will collectively surpass $1bn in sales in the same year, becoming responsible for nearly 80% of the total market share for rituximab products.

Sales 59

Sales Competition Marketing Patients 59

Pharmaceutical Technology

JUNE 13, 2023

The agent is being evaluated in relapsed/refractory (R/R) patients who have KMT2A-rearranged (KMT2ar) or NPM1-mutant (NPM1m) acute myeloid leukaemia (AML). Ziftomenib targets the menin-KMT2a protein-protein interaction that may occur in patients with KMT2ar or NPM1m genetic alterations. months for all patients achieving CRc.

Patients 52

Patients Sales Competition Safety 52

Medico Reach

OCTOBER 17, 2022

billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The device replaces a connecting bone in the ankle joint and can be customized according to patient preference.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Medico Reach

OCTOBER 17, 2022

billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The device replaces a connecting bone in the ankle joint and can be customized according to patient preference.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52